Author:
Warrington S.,Debbas N.,Farthing M.,Horton M.,Thillainayagam A.,Umile A.
Reference14 articles.
1. Acerbi D., Bonati C., Boscarino G., Bufalino L., Cesari F. et al. Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam-β-cyclodextrin. Int J Clin Pharmacol Res. 1988;8:175–180.
2. Acerbi D., Lebacq Jr E., Rondelli I., Stockis A., Ventura P. Rapid oral absorption profile of piroxicam from its beta-cyclodextrin complex. Drug Invest. 1990;2(Suppl. 4):50–55.
3. Tiengo M. Review of the analgesic activity effects of piroxicam-β-cyclodextrin. Drug Invest. 1990;2(Suppl. 4):61–66.
4. Patoia L., Clausi G., Farroni F., Alberti P., Fugiani P., Bufalino L. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam-β-cyclodextrin, piroxicam and placebo administration. Eur J Clin Pharmacol. 1989;36:599–604.
5. Santucci L., Fiorucci S., Patoia L, Farroni F, Sicilia A., Chiucchiu S., Bufalino L., Morelli A. Gastric tolerance of piroxicam-beta-cyclodextrin compared with placebo and with other NSAIDs: An endoscopic and functional study by evaluation of transmucosal potential differences. Drug Invest. 1990;2(Suppl. 4):56–60.